Statistics

 array:17 [
  "pii" => "13003923"
  "issn" => "03010546"
  "estado" => "S300"
  "fechaPublicacion" => "1998-07-01"
  "documento" => "article"
  "crossmark" => 0
  "subdocumento" => "fla"
  "cita" => "Allergol  Immunopathol (Madr). 1998;26:201"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 2395
    "formatos" => array:3 [
      "EPUB" => 8
      "HTML" => 2372
      "PDF" => 15
    ]
  ]
  "itemAnterior" => array:15 [
    "pii" => "13003922"
    "issn" => "03010546"
    "estado" => "S300"
    "fechaPublicacion" => "1998-07-01"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "fla"
    "cita" => "Allergol  Immunopathol (Madr). 1998;26:199-200"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 1667
      "formatos" => array:3 [
        "EPUB" => 9
        "HTML" => 1635
        "PDF" => 23
      ]
    ]
    "en" => array:6 [
      "idiomaDefecto" => true
      "titulo" => "Anaphylaxis to paracetamol."
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "199"
          "paginaFinal" => "200"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "P A Galindo, J Borja, P Mur, F Feo, E Gómez"
          "autores" => array:5 [
            0 => array:2 [
              "Iniciales" => "P A"
              "apellidos" => "Galindo"
            ]
            1 => array:2 [
              "Iniciales" => "J"
              "apellidos" => "Borja"
            ]
            2 => array:2 [
              "Iniciales" => "P"
              "apellidos" => "Mur"
            ]
            3 => array:2 [
              "Iniciales" => "F"
              "apellidos" => "Feo"
            ]
            4 => array:2 [
              "Iniciales" => "E"
              "apellidos" => "Gómez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13003922?idApp=UINPBA00004N"
    "url" => "/03010546/0000002600000004/v0_201402051326/13003922/v0_201402051326/en/main.assets"
  ]
  "en" => array:7 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">NEWS</span>"
    "titulo" => "NEWS"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "201"
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara">ALLERGOL&#46; ET IMMUNOPATHOL&#46;&#44; 1998&#59;26&#40;4&#41;&#58;201</p><p class="elsevierStylePara">NEWS</p><p class="elsevierStylePara"><span class="elsevierStyleBold">PATIENT ACCEPTANCE AND SHORTENED CYCLES PAINT OPTIMISTIC FUTURE FOR THERAPEUTIC VACCINE MANUFACTURERS</span></p><p class="elsevierStylePara"><span class="elsevierStyleItalic">Mountain View&#44; California&#46;</span> Viruses are difficult to treat because they mutate rendering initially effective drugs useless against new viral strains&#46; By targeting only the highly conserved areas of viral protein&#44; protein-based or deoxyribonucleic acid &#40;DNA&#41; therapeutic vaccines hope to become the treatment breakthrough patients have been waiting for&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleItalic">World Therapeutic Vaccines Market&#46;</span> Studies the market potential for therapeutic vaccines treating AISD&#44; cancer and autoimmune diseases&#46; The study spotlights each disease individually to give an in-depth examination of the discovery&#44; research and developmental phases of market participants&#46;</p><p class="elsevierStylePara">The significant acceleration of drug approval by the FDA is very encouraging to manufacturers in all markets&#46; Through the Prescription Drug User Fee Act &#40;PDUFA&#41;&#44; the FDA collects fees from drug companies to increase its resources and shorten approval time&#46; The Biotechnology Industry Organization &#40;BIO&#41; is working with the FDA to formulate PDUFA II that would mean a further reduction from 27 to 15 months&#46;</p><p class="elsevierStylePara">Physician and patient acceptance toward therapeutic vaccines is high&#44; especially for life-threatening illnesses such as AIDS and cancer&#46; Once this perception is confirmed by clinical trial results&#44; the market for therapeutic vaccines may expand tremendously as it begins to include patients who previously would not have considered these alternative treatments&#46;</p><p class="elsevierStylePara">&#34;In terms of patient populations&#44; the market opportunity is large&#44; but the types of treatments available on the market will help in defining acceptance by patients&#34;&#44; said Archana Asthana&#44; medical analyst at Frost &#38; Sullivan&#46;</p><p class="elsevierStylePara">&#34;Often&#44; therapies are not available to the average patient&#44; or are highly toxic if available&#46; New products could meet with great success&#44; if they can be effective&#44; accessible and nontoxic&#34;&#46;</p><p class="elsevierStylePara">The first therapeutic vaccine is scheduled to enter the market in 1998 to treat melanoma cancer&#46; Cancer has received encouragement through clinical trials from the targeted population&#44; and the long term effects on survival and recurrence are eagerly awaited&#46; Therapeutic vaccines for breast&#44; stomach and ovarian cancer are also expected to become available shortly after the turn of the century&#46;</p><p class="elsevierStylePara">The positive clinical results from combination triple drug therapy originally caused a stir among AIDS patients&#44; but this enthusiasm has been tempered by the eventual drug resistance found in some patients&#46; Researchers are hoping that The Immune Response Corporation&#39;&#39;s therapeutic vaccine Remune&#44; slated for a 1999 release&#44; will provide better long term results&#46;</p><p class="elsevierStylePara">Critical phases of the research included&#58; identification of industry challenges&#44; market engineering measurements&#44; strategic recommendations&#44; planning and market monitoring&#46; All of the vital elements of this system help the market participants navigate successfully through the therapeutic vaccine markets &#40;www&#46;frost&#46;com&#41;&#46;</p><table><tr><td colspan="4"><span class="elsevierStyleBold">Total Therapeutic Vaccines Market&#58;</span></td></tr><tr><td colspan="4"><span class="elsevierStyleBold"> Revenue Forecasts &#40;World&#41;&#44; 1997-2003</span></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td></td><td></td><td></td><td><p class="elsevierStylePara"><span class="elsevierStyleItalic">Revenue</span></p></td></tr><tr align="CENTER"><td><span class="elsevierStyleItalic"> Rate</span></td><td colspan="2"><span class="elsevierStyleItalic"> Revenues</span></td><td><span class="elsevierStyleItalic"> Growth</span></td></tr><tr align="CENTER"><td><span class="elsevierStyleItalic"> Year</span></td><td colspan="2"><span class="elsevierStyleItalic">&#40;&#36; Million&#41;</span></td><td><span class="elsevierStyleItalic"> &#40;&#37;&#41;</span></td></tr><tr align="CENTER"><td>1997 </td><td colspan="2"> 0&#46;0</td><td>&#173;</td></tr><tr align="CENTER"><td>1998</td><td colspan="2"> 2&#46;1</td><td>&#173;</td></tr><tr align="CENTER"><td>1999</td><td colspan="2"> 79&#46;4</td><td>3&#44;679&#46;5</td></tr><tr align="CENTER"><td>2000</td><td colspan="2"> 213&#46;5</td><td>169&#46;0</td></tr><tr align="CENTER"><td>2001</td><td colspan="2"> 566&#46;2</td><td>165&#46;1</td></tr><tr align="CENTER"><td>2002</td><td colspan="2"> 721&#46;5</td><td>27&#46;4</td></tr><tr align="CENTER"><td>2003</td><td colspan="2"> 926&#46;8</td><td>28&#46;4</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td colspan="4">Compound Annual Growth Rate &#40;1998-2003&#41;&#58; 213&#46;3&#37;<br></br> Source&#58; Frost &#38; Sullivan&#44; Report 5349&#46;</td></tr></table>"
    "tienePdf" => false
  ]
  "idiomaDefecto" => "en"
  "url" => "/03010546/0000002600000004/v0_201402051326/13003923/v0_201402051326/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6757"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "News"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13003923?idApp=UINPBA00004N"
]